Literature DB >> 23329331

Ocular neovascularization.

Peter A Campochiaro1.   

Abstract

Retinal and choroidal vascular diseases constitute the most common causes of moderate and severe vision loss in developed countries. They can be divided into retinal vascular diseases, in which there is leakage and/or neovascularization (NV) from retinal vessels, and subretinal NV, in which new vessels grow into the normally avascular outer retina and subretinal space. The first category of diseases includes diabetic retinopathy, retinal vein occlusions, and retinopathy of prematurity, and the second category includes neovascular age-related macular degeneration (AMD), ocular histoplasmosis, pathologic myopia, and other related diseases. Retinal hypoxia is a key feature of the first category of diseases resulting in elevated levels of hypoxia-inducible factor-1 (HIF-1) which stimulates expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor-B (PDGF-B), placental growth factor, stromal-derived growth factor-1 and their receptors, as well as other hypoxia-regulated gene products such as angiopoietin-2. Although hypoxia has not been demonstrated as part of the second category of diseases, HIF-1 is elevated and thus the same group of hypoxia-regulated gene products plays a role. Clinical trials have shown that VEGF antagonists provide major benefits for patients with subretinal NV due to AMD and even greater benefits are seen by combining antagonists of VEGF and PDGF-B. It is likely that addition of antagonists of other agents listed above will be tested in the future. Other appealing strategies are to directly target HIF-1 or to use gene transfer to express endogenous or engineered anti-angiogenic proteins. While substantial progress has been made, the future looks even brighter for patients with retinal and choroidal vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329331      PMCID: PMC3584193          DOI: 10.1007/s00109-013-0993-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  105 in total

1.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors:  P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.

Authors:  T N Sato; Y Tozawa; U Deutsch; K Wolburg-Buchholz; Y Fujiwara; M Gendron-Maguire; T Gridley; H Wolburg; W Risau; Y Qin
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

3.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

Authors:  Peter A Campochiaro; Quan Dong Nguyen; Syed Mahmood Shah; Michael L Klein; Eric Holz; Robert N Frank; David A Saperstein; Anurag Gupta; J Timothy Stout; Jennifer Macko; Robert DiBartolomeo; Lisa L Wei
Journal:  Hum Gene Ther       Date:  2006-02       Impact factor: 5.695

4.  Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1.

Authors:  Huasheng Lu; Clifton L Dalgard; Ahmed Mohyeldin; Thomas McFate; A Sasha Tait; Ajay Verma
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

5.  The role of adult bone marrow-derived stem cells in choroidal neovascularization.

Authors:  Nilanjana Sengupta; Sergio Caballero; Robert N Mames; Jason M Butler; Edward W Scott; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

6.  Opposite roles of CCR2 and CX3CR1 macrophages in alkali-induced corneal neovascularization.

Authors:  Peirong Lu; Longbiao Li; Gaoqin Liu; Nico van Rooijen; Naofumi Mukaida; Xueguang Zhang
Journal:  Cornea       Date:  2009-06       Impact factor: 2.651

7.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

Authors:  M Friedlander; C L Theesfeld; M Sugita; M Fruttiger; M A Thomas; S Chang; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

10.  Macrophages inhibit neovascularization in a murine model of age-related macular degeneration.

Authors:  Rajendra S Apte; Jennifer Richter; John Herndon; Thomas A Ferguson
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  135 in total

Review 1.  The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity.

Authors:  D Kent
Journal:  Eye (Lond)       Date:  2015-07-31       Impact factor: 3.775

2.  Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro.

Authors:  R K Vadlapatla; A D Vadlapudi; D Pal; M Mukherji; A K Mitra
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

3.  Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration.

Authors:  Nurgül Örnek; Kemal Örnek; Süleyman Aydin; Musa Yilmaz; Yaşar Ölmez
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

4.  Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.

Authors:  Wentao Luo; Liumei Hu; Weiye Li; Guotong Xu; Linxinyu Xu; Conghui Zhang; Fang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 3.117

5.  Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.

Authors:  Patrick Koenig; Chingwei V Lee; Sarah Sanowar; Ping Wu; Jeremy Stinson; Seth F Harris; Germaine Fuh
Journal:  J Biol Chem       Date:  2015-06-18       Impact factor: 5.157

6.  Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.

Authors:  Sheik Pran Babu Sardar Pasha; Kamakshi Sishtla; Rania S Sulaiman; Bomina Park; Trupti Shetty; Fenil Shah; Melissa L Fishel; James H Wikel; Mark R Kelley; Timothy W Corson
Journal:  J Pharmacol Exp Ther       Date:  2018-08-03       Impact factor: 4.030

7.  Blood vessels, disease pathogenesis, and novel therapies.

Authors:  Gregg L Semenza
Journal:  J Mol Med (Berl)       Date:  2013-03       Impact factor: 4.599

8.  Long non-coding RNAs: new players in ocular neovascularization.

Authors:  Xue-Dong Xu; Ke-Ran Li; Xiu-Miao Li; Jin Yao; Jiang Qin; Biao Yan
Journal:  Mol Biol Rep       Date:  2014-03-13       Impact factor: 2.316

9.  Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

Authors:  Gabriela D'Amico; Emilia A Korhonen; Andrey Anisimov; Georgia Zarkada; Tanja Holopainen; René Hägerling; Friedemann Kiefer; Lauri Eklund; Raija Sormunen; Harri Elamaa; Rolf A Brekken; Ralf H Adams; Gou Young Koh; Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

10.  Targeting long non-coding RNA MALAT1 alleviates retinal neurodegeneration in diabetic mice.

Authors:  Yu-Lan Zhang; Han-Ying Hu; Zhi-Peng You; Bing-Yang Li; Ke Shi
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.